Novara Mark David's most recent trade in Tandem Diabetes Care Inc was a trade of 7,414 Restricted Stock Unit done . Disclosure was reported to the exchange on June 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 7,414 | 44,488 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 7,414 | 32,609 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.76 per share. | 16 Jun 2025 | 3,846 | 28,763 (0%) | 0% | 20.8 | 79,843 | Common Stock |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 31,488 | 31,488 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 31,486 | 31,486 | - | - | Performance Stock Unit | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 19.30 per share. | 15 May 2025 | 870 | 25,004 (0%) | 0% | 19.3 | 16,791 | Common Stock |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 304 | 609 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 304 | 25,308 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.70 per share. | 15 May 2025 | 113 | 25,195 (0%) | 0% | 22.7 | 2,565 | Common Stock |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 7,415 | 26,873 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 7,415 | 51,902 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.17 per share. | 17 Mar 2025 | 2,739 | 24,134 (0%) | 0% | 19.2 | 52,507 | Common Stock |
| Tandem Diabetes Care Inc | Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 29,658 | 30,190 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 29,658 | 59,317 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.66 per share. | 16 Dec 2024 | 10,732 | 19,458 (0%) | 0% | 32.7 | 350,507 | Common Stock |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 23.24 per share. | 15 Nov 2024 | 532 | 532 (0%) | 0% | 23.2 | 12,364 | Common Stock |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 913 | 913 | - | - | Performance Stock Unit | |
| Tandem Diabetes Care Inc | Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 913 | 913 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 88,975 | 88,975 | - | - | Restricted Stock Unit |